Loading clinical trials...
Loading clinical trials...
The primary objective of the study is to evaluate the safety and tolerability of multiple-ascending doses of GTX-102 administered by intrathecal (IT) injection to participants with Angelman Syndrome (...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Ultragenyx Pharmaceutical Inc
NCT06139172 · Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, and more
NCT06337383 · Angelman Syndrome
NCT05630066 · Angelman Syndrome
NCT04428281 · Angelman Syndrome
NCT02996305 · Angelman Syndrome
UCLA Medical Center
Los Angeles, California
Rady Children's Hospital
San Diego, California
Rare Disease Research
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions